Class Action Lawsuits Filed Against Gossamer Bio and Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy MEDP?
Source: Globenewswire
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 420.670
Low
462.00
Averages
569.17
High
660.00
Current: 420.670
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing allegations of false statements during the class period from February 7, 2025, to February 12, 2026, which may lead to significant revenue losses and potential restructuring, with a lead plaintiff deadline of May 29, 2026.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, with a lead plaintiff deadline of June 1, 2026.
- Gossamer Bio Lawsuit Details: Gossamer Bio, Inc. faces claims of failing to disclose the failure of its clinical trial from June 16, 2025, to February 20, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Lawsuit Information: Medpace Holdings, Inc. is accused of making false statements regarding its financial metrics from April 22, 2025, to February 9, 2026, with a lead plaintiff deadline of June 8, 2026, potentially impacting the company's future financing capabilities.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies like Gossamer Bio, urging affected shareholders to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- Gossamer Bio Allegations: During the period from June 16, 2025, to February 20, 2026, Gossamer Bio is accused of failing to disclose critical issues in its clinical trials, resulting in its Phase 3 PROSERA study not meeting primary endpoints, which negatively impacted investor confidence.
- New Era Energy Allegations: From November 6, 2024, to December 29, 2025, New Era Energy is alleged to have overstated progress on its Texas Critical Data Centers project and engaged in fraudulent schemes, leading to misleading financial results that affected shareholders.
- Medpace Holdings Allegations: During the period from April 22, 2025, to February 9, 2026, Medpace Holdings is accused of overstating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations on its business, misleading investors about its operational health.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. faces allegations of securities fraud for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a 16% stock drop in a single day, from $530.35 to $446.05 per share, with investors urged to act by June 8, 2026.
- Legal Action Progress: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP against Medpace and certain executives, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, which could impact the company's reputation and future financing capabilities.
- Misleading Financial Data: Medpace reported a decline in its book-to-bill ratio to 1.04 in its Q4 2025 financial results released on February 9, 2026, due to increased cancellation rates, contradicting previous statements, which may lead to a decline in investor confidence.
- Executive Departure Impact: The resignation of Medpace President Jesse Geiger has heightened market concerns regarding the company's future, causing the stock price to drop approximately 23% during trading on April 23, 2026, reflecting investor skepticism about corporate governance and operational transparency.
See More
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline exceeding 15.9%, after revealing a Q4 2025 book-to-bill ratio of only 1.04x, significantly below the projected 1.15x, which directly undermines investor confidence and market performance.
- Discrepancy Between Internal Data and Public Statements: The lawsuit alleges that Medpace's leadership had access to internal data indicating high cancellation rates yet publicly portrayed a picture of robust business health, potentially leading to legal liabilities for misleading investors about the company's true financial condition.
- Fluctuating Cancellation Rates Raise Red Flags: Management described cancellation rates as
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Medpace Holdings Inc. and its executives for securities fraud, reflecting significant investor concerns regarding the company's financial transparency after a substantial stock drop.
- Stock Price Plunge: Following the release of its financial results on February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a drop of 15.9%, indicating a loss of market confidence in its financial health.
- Executive Departure: The resignation of Medpace's President, Jesse Geiger, after the stock decline adds to the uncertainty surrounding the company's future, potentially undermining investor trust and shareholder value.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, Medpace may face substantial damages that could impact its financial condition and future fundraising capabilities.
See More
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing allegations of false statements during the class period from February 7, 2025, to February 12, 2026, which may lead to significant revenue losses and potential restructuring, with a lead plaintiff deadline of May 29, 2026.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, with a lead plaintiff deadline of June 1, 2026.
- Gossamer Bio Lawsuit Details: Gossamer Bio, Inc. faces claims of failing to disclose the failure of its clinical trial from June 16, 2025, to February 20, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Lawsuit Information: Medpace Holdings, Inc. is accused of making false statements regarding its financial metrics from April 22, 2025, to February 9, 2026, with a lead plaintiff deadline of June 8, 2026, potentially impacting the company's future financing capabilities.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies like Gossamer Bio, urging affected shareholders to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- Gossamer Bio Allegations: During the period from June 16, 2025, to February 20, 2026, Gossamer Bio is accused of failing to disclose critical issues in its clinical trials, resulting in its Phase 3 PROSERA study not meeting primary endpoints, which negatively impacted investor confidence.
- New Era Energy Allegations: From November 6, 2024, to December 29, 2025, New Era Energy is alleged to have overstated progress on its Texas Critical Data Centers project and engaged in fraudulent schemes, leading to misleading financial results that affected shareholders.
- Medpace Holdings Allegations: During the period from April 22, 2025, to February 9, 2026, Medpace Holdings is accused of overstating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations on its business, misleading investors about its operational health.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. faces allegations of securities fraud for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a 16% stock drop in a single day, from $530.35 to $446.05 per share, with investors urged to act by June 8, 2026.
- Legal Action Progress: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP against Medpace and certain executives, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, which could impact the company's reputation and future financing capabilities.
- Misleading Financial Data: Medpace reported a decline in its book-to-bill ratio to 1.04 in its Q4 2025 financial results released on February 9, 2026, due to increased cancellation rates, contradicting previous statements, which may lead to a decline in investor confidence.
- Executive Departure Impact: The resignation of Medpace President Jesse Geiger has heightened market concerns regarding the company's future, causing the stock price to drop approximately 23% during trading on April 23, 2026, reflecting investor skepticism about corporate governance and operational transparency.
See More
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline exceeding 15.9%, after revealing a Q4 2025 book-to-bill ratio of only 1.04x, significantly below the projected 1.15x, which directly undermines investor confidence and market performance.
- Discrepancy Between Internal Data and Public Statements: The lawsuit alleges that Medpace's leadership had access to internal data indicating high cancellation rates yet publicly portrayed a picture of robust business health, potentially leading to legal liabilities for misleading investors about the company's true financial condition.
- Fluctuating Cancellation Rates Raise Red Flags: Management described cancellation rates as
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Medpace Holdings Inc. and its executives for securities fraud, reflecting significant investor concerns regarding the company's financial transparency after a substantial stock drop.
- Stock Price Plunge: Following the release of its financial results on February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a drop of 15.9%, indicating a loss of market confidence in its financial health.
- Executive Departure: The resignation of Medpace's President, Jesse Geiger, after the stock decline adds to the uncertainty surrounding the company's future, potentially undermining investor trust and shareholder value.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, Medpace may face substantial damages that could impact its financial condition and future fundraising capabilities.
See More
